Division of Metabolism, Endocrinology and Nutrition, Department of Medicine (C.C.H., J.E.K., V.K., K.E.B.), University of Washington Medicine Diabetes Institute, University of Washington, Seattle.
Department of Laboratory Medicine and Pathology (K.E.B.), University of Washington Medicine Diabetes Institute, University of Washington, Seattle.
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1124-1133. doi: 10.1161/ATVBAHA.122.318290. Epub 2023 May 25.
APOA1 and APOB are the structural proteins of high-density lipoprotein and APOB-containing lipoproteins, such as low-density lipoprotein and very low-density lipoprotein, respectively. The 4 smaller APOCs (APOC1, APOC2, APOC3, and APOC4) are exchangeable apolipoproteins; they are readily transferred among high-density lipoproteins and APOB-containing lipoproteins. The APOCs regulate plasma triglyceride and cholesterol levels by modulating substrate availability and activities of enzymes interacting with lipoproteins and by interfering with APOB-containing lipoprotein uptake through hepatic receptors. Of the 4 APOCs, APOC3 has been best studied in relation to diabetes. Elevated serum APOC3 levels predict incident cardiovascular disease and progression of kidney disease in people with type 1 diabetes. Insulin suppresses APOC3 levels, and accordingly, elevated APOC3 levels associate with insulin deficiency and insulin resistance. Mechanistic studies in a mouse model of type 1 diabetes have demonstrated that APOC3 acts in the causal pathway of diabetes-accelerated atherosclerosis. The mechanism is likely due to the ability of APOC3 to slow the clearance of triglyceride-rich lipoproteins and their remnants, thereby causing an increased accumulation of atherogenic lipoprotein remnants in lesions of atherosclerosis. Less is known about the roles of APOC1, APOC2, and APOC4 in diabetes.
载脂蛋白 A1 和载脂蛋白 B 分别是高密度脂蛋白和载脂蛋白 B 脂蛋白(如低密度脂蛋白和极低密度脂蛋白)的结构蛋白。4 种较小的载脂蛋白 C(载脂蛋白 C1、载脂蛋白 C2、载脂蛋白 C3 和载脂蛋白 C4)是可交换的载脂蛋白;它们可在高密度脂蛋白和载脂蛋白 B 脂蛋白之间轻易转移。载脂蛋白 C 通过调节与脂蛋白相互作用的酶的底物可用性和活性,以及通过干扰通过肝受体摄取载脂蛋白 B 脂蛋白,来调节血浆甘油三酯和胆固醇水平。在这 4 种载脂蛋白 C 中,载脂蛋白 C3 与糖尿病的关系研究得最多。血清载脂蛋白 C3 水平升高可预测 1 型糖尿病患者发生心血管疾病和肾脏疾病进展。胰岛素抑制载脂蛋白 C3 水平,因此,升高的载脂蛋白 C3 水平与胰岛素缺乏和胰岛素抵抗有关。1 型糖尿病小鼠模型的机制研究表明,载脂蛋白 C3 在糖尿病加速动脉粥样硬化的因果途径中起作用。其机制可能是由于载脂蛋白 C3 能够减缓富含甘油三酯的脂蛋白及其残片的清除速度,从而导致动脉粥样硬化病变中致动脉粥样硬化脂蛋白残片的积累增加。关于载脂蛋白 C1、载脂蛋白 C2 和载脂蛋白 C4 在糖尿病中的作用,了解较少。